Clinical Trials Logo

Hypoxia clinical trials

View clinical trials related to Hypoxia.

Filter by:
  • Available  
  • Page 1

NCT ID: NCT04657458 Available - Covid19 Clinical Trials

Expanded Access for Use of bmMSC-Derived Extracellular Vesicles in Patients With COVID-19 Associated ARDS

Start date: n/a
Phase:
Study type: Expanded Access

ExoFlo, Bone Marrow Mesenchymal Stem Cell Derived Extracellular Vesicles Allograft Product, Infusion Treatment is currently being studied in Protocol DB-EF-PhaseIII-0001 in patients COVID-19 associated moderate to severe acute respiratory distress syndrome (ARDS). This expanded access protocol is an open label study intended to provide ExoFlo to critically ill patients who do not qualify for the Phase III randomized controlled trial (RCT) because they - Do not meet phase III eligibility criteria at current phase III sites. - Do meet phase III eligibility criteria but cannot access phase III sites. - Do not meet phase III eligibility criteria & cannot access phase III sites.

NCT ID: NCT03327467 Available - Cerebral Palsy Clinical Trials

Expanded Access Protocol: Umbilical Cord Blood Infusions for Children With Brain Injuries

Start date: n/a
Phase:
Study type: Expanded Access

The purpose of this protocol is to enable access to intravenous infusions of banked autologous (a person's own) or sibling umbilical cord blood (CB) for children with various brain disorders. This is an expanded access protocol intended for patients who are unable to participate in a clinical trial involving their own or their sibling's cord blood. Children with cerebral palsy, congenital hydrocephalus, apraxia, stroke, hypoxic brain injury and related conditions will be eligible if they have normal immune function and do not qualify for, have previously participated in, or are unable to participate in an active cell therapy clinical trial at Duke Medicine. For the purpose of this protocol the term children refers to patients less than 26 years of age. The cord blood is thawed and then administered as an intravenous infusion. Recipients do not receive chemotherapy or immunosuppression. The mechanism of action is through paracrine signaling of cord blood monocytes inducing endogenous cells to repair existing damage.